Freenome, Inc. (NASDAQ: FRNM) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $80M. The Maz Rating grades it against the other companies in its sector.
Freenome, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.82, Freenome, Inc. trades at 0.4x sales and 2.0x book value. Over the last twelve months it generated about $218M of revenue and a net loss of $47M. It runs a gross margin of 47.8%, an operating margin of -43.8% and a net margin of -50.8%. It shows return on equity of -60.3%, return on invested capital of -13.5% and a free cash flow yield of -190.4%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 12.73. Over the past 52 weeks the share price ranged from $9.71 to $17.50, with a beta of 0.35.
Freenome, Inc. does not currently pay a dividend.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Freenome, Inc. (FRNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 87.7% / 30% · (Cash+Inv) / Mkt Cap (36m) 198.6% / 30% · Interest income / Revenue 1.62% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 87.7% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 198.6% / 33% · Receivables / Mkt Cap (36m) 4.07% / 49% · Interest income / Revenue 1.62% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 87.7% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 198.6% / 33.33% · Receivables / Mkt Cap (24m) 4.07% / 33.33% · Interest income / Revenue 1.62% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 18.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.9% / 33.33% · Receivables / Avg Assets (4Q) 0.90% / 33.33% · Interest income / Revenue 1.62% / 5% | Fail |
| FTSE | Debt / Total Assets 25.9% / 33.33% · (Cash+ST Inv) / Total Assets 58.6% / 33.33% · (Cash+Recv) / Total Assets 59.8% / 33.33% · Interest income / Revenue 1.62% / 5% | Fail |
No. As of September 2026, Freenome, Inc. (FRNM) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Freenome, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 1.62% of each dividend: Freenome, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.